Investors looking for undervalued gems in the health care sector find solace in the most oversold stocks, offering a potential avenue for significant gains.
One key measure, the Relative Strength Index (RSI), paints a picture of a stock’s strength on days of price increases against days of price drops. An RSI below 30 signifies oversold territory, providing insights on potential short-term performance. This metric, as per financial platform Benzinga Pro, is a valuable tool for astute traders.
Let’s delve into the top three health care stocks showing notable oversold conditions:
Organon & Co (NYSE: OGN)
- Organon is gearing up to unveil its third-quarter results on October 31. The company’s stock underwent a 12% dip over the last month, with a 52-week low of $10.84.
- RSI Value: 28.28
- OGN Price Action: Organon shares closed at $17.45 on Monday, marking a 0.9% decline.
- Noteworthy alerts from Benzinga Pro’s newsfeed provide investors with timely updates on Organon’s developments.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)
- Arcutis Biotherapeutics received the stamp of approval from Health Canada for ZORYVE® Foam on Oct. 21, offering a treatment option for seborrheic dermatitis in individuals aged 9 and above. Noted dermatologist Dr. Melinda Gooderham commended the approval, citing impressive success rates from clinical trials. The company saw a 14% decline in its stock over the past five days, touching a 52-week low of $1.76.
- RSI Value: 28.13
- ARQT Price Action: Shares of Arcutis Biotherapeutics closed at $8.31 on Monday, reflecting a 4.7% decrease.
- Insights from Benzinga Pro’s charting tool play a crucial role in tracking the trajectory of ARQT stock.
TransMedics Group Inc (NASDAQ: TMDX)
- TransMedics Group is set to disclose its third-quarter financial results after Monday’s market closure on Oct. 28. The company witnessed a 22% slump in its shares over the past month, touching a 52-week low of $36.42.
- RSI Value: 29.60
- TMDX Price Action: TransMedics shares wrapped up Monday at $124.48, signaling a 1.7% downturn.
- The significant dip in TransMedics’ shares caught the attention of investors, thanks to Benzinga Pro’s signals feature.
Seize the potential in health care stocks ripe for a rebound with fresh insights and data analysis.
Market News and Data brought to you by Benzinga APIs